James Samuel Shannon - 11 Jun 2025 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Director
Signature
/s/ Kevin Brennan, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
11 Jun 2025
Net transactions value
$0
Form type
4
Filing time
12 Jun 2025, 16:35:17 UTC
Previous filing
16 May 2025
Next filing
18 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shannon James Samuel Director 828 WINTER STREET, SUITE 300, WALTHAM /s/ Kevin Brennan, Attorney-in-Fact 12 Jun 2025 0001485417

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +31,000 $0.000000 31,000 11 Jun 2025 Common Stock 31,000 $0.6930 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.